2. Academic Validation
  3. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma

Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma

  • Br J Haematol. 2020 May;189(4):731-744. doi: 10.1111/bjh.16435.
Dachuan Huang 1,  Tammy Linlin Song 1,  Maarja-Liisa Nairismägi 1,  Yurike Laurensia 1,  Wan-Lu Pang 1,  Daryl Cheah Ming Zhe 1,  Esther Kam Yin Wong 1,  Giovani Giovani-Clarest Wijaya 2,  Jing Tan 2,  Sze Huey Tan 3,  Jing-Quan Lim 1,  Burton Kuan Hui Chia 1,  Jason Yongsheng Chan 4,  Tiffany Pooi Ling Tang 4,  Nagavalli Somasundaram 4,  Chee Leong Cheng 5,  Oliver Politz 6,  Ningshu Liu 6,  Soon Thye Lim 4 7,  Choon Kiat Ong 1 7 8
Affiliations

Affiliations

  • 1 Lymphoma Genomic Translational Research Laboratory, Division of Cellular & Molecular Research, National Cancer Centre Singapore, Singapore City, Singapore.
  • 2 Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore City, Singapore.
  • 3 Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore City, Singapore.
  • 4 Division of Medical Oncology, National Cancer Centre Singapore, Singapore City, Singapore.
  • 5 Department of Pathology, Singapore General Hospital, Singapore City, Singapore.
  • 6 Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
  • 7 Duke-NUS Medical School, Singapore City, Singapore.
  • 8 Genome Institute of Singapore, A*STAR.
PMID: 32004387 DOI: 10.1111/bjh.16435
Abstract

Peripheral T-cell lymphomas (PTCL) and natural killer (NK)/T-cell lymphomas (NKTCL) are a heterogeneous group of aggressive malignancies with dismal outcomes and limited treatment options. While the phosphatidylinositol 3-kinase (PIK3) pathway has been shown to be highly activated in many B-cell lymphomas, its therapeutic relevance in PTCL and NKTCL remains unclear. The aim of this study is to investigate the expression of PIK3 and Phosphatase and tensin homolog (PTEN) in these subtypes of lymphoma and to identify potential therapeutic targets for clinical testing. Therefore, the expression of PIK3α, PIK3β, PIK3γ, PIK3δ and PTEN was analyzed in 88 cases of PTCL and NKTCL samples by immunohistochemistry. All PTCL and NKTCL samples demonstrated high expression of PIK3 isoforms. In particular, high PIK3α expression was significantly associated with poor survival, even after adjustment for age, International Prognostic Index (IPI) score and anthracycline-based chemotherapy in first line. Notably, copanlisib, a pan-class I inhibitor with predominant activities towards PIK3α and PIK3δ isoforms, effectively inhibited phosphorylation of Akt, 4E-BP-1 and STAT3, causing G0 /G1 cell cycle arrest and resulting in suppression of tumour cell growth in vitro and in vivo. This study provides evidence that targeting the PIK3 pathway, particularly simultaneous inhibition of PIK3α and δ, could be a promising approach for the treatment of PTCL and NKTCL.

Keywords

NK/T-cell lymphoma; PI3K; copanlisib; peripheral T-cell lymphoma; phosphatidylinositol 3-kinase.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z